OTCMKTS:GBIM Globeimmune (GBIM) Stock Price, News & Analysis $0.0001 0.00 (0.00%) As of 09/29/2026 03:48 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChart About Globeimmune Stock (OTCMKTS:GBIM) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Globeimmune alerts:Sign Up Key Stats Today's Range$0.0001▼$0.000150-Day Range N/A52-Week Range$0.00▼$0.04Volume12,537 shsAverage Volume3,775 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview GlobeImmune, Inc. was a biotechnology company focused on developing therapeutic vaccines and immunotherapies for cancer and infectious diseases. The company’s platform, known as Tarmogens, was designed to stimulate targeted immune responses against disease-associated proteins. GlobeImmune’s development programs included investigational treatments directed at cancer targets such as mutant RAS proteins and telomerase, as well as programs for chronic infectious diseases including hepatitis C and tuberculosis. Its products were in the research and clinical-development stages and were not established commercial therapies. Based in Colorado, GlobeImmune conducted its activities primarily through research and clinical-development programs in the United States. Public information about the company’s current operating activities and leadership is limited; GlobeImmune was historically a development-stage biotechnology company whose programs and corporate status changed substantially after it discontinued or reassessed several clinical initiatives.AI Generated. May Contain Errors. Read More Receive GBIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Globeimmune and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GBIM Stock News HeadlinesGlobeImmune Inc.August 18, 2026 | marketwatch.comGlobeImmune, Inc. (GBIM) - Yahoo FinanceJune 27, 2025 | sg.finance.yahoo.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.September 30 at 1:00 AM | Stansberry Research (Ad)GlobeImmune, Inc. (GBIM)October 20, 2024 | finance.yahoo.comBSPM Biostar Pharmaceuticals, Inc.May 14, 2024 | seekingalpha.comBubang Co Ltd (014470)July 18, 2023 | investing.comNihon Knowledge Co Ltd (5252)July 18, 2023 | investing.comNuvista Energy Breaks Below 200-Day Moving Average - Notable for NVAApril 21, 2023 | nasdaq.comSee More Headlines GBIM Stock Analysis - Frequently Asked Questions How have GBIM shares performed this year? Globeimmune's stock was trading at $0.0001 at the beginning of 2026. Since then, GBIM stock has increased by 0.0% and is now trading at $0.0001. How were Globeimmune's earnings last quarter? Globeimmune, Inc. (OTCMKTS:GBIM) announced its quarterly earnings data on Thursday, May, 12th. The biopharmaceutical company reported ($0.15) EPS for the quarter, beating analysts' consensus estimates of ($0.27) by $0.12. The biopharmaceutical company earned $0.94 million during the quarter. How do I buy shares of Globeimmune? Shares of GBIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Globeimmune own? Based on aggregate information from My MarketBeat watchlists, some other companies that Globeimmune investors own include Novavax (NVAX), Premier Gold Mines (PG), Algonquin Power & Utilities (AQN), Nordic American Tankers (NAT), Petroleo Brasileiro S.A.- Petrobras (PBR). Company Calendar Last Earnings5/12/2016Today9/30/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolOTCMKTS:GBIM Previous SymbolNASDAQ:GBIM CIK1245104 Webwww.globeimmune.com Phone(720) 667-2300Fax303-625-2710Employees3Year Founded1995Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A 10 Best Stocks to Own in Fall 2026AI spending is reshaping the market, and the opportunity extends far beyond the biggest chipmakers. Discover 10 stocks set to benefit from powerful trends in AI infrastructure, cloud computing, energy, capital returns, and consumer growth this fall.Get This Free Report This page (OTCMKTS:GBIM) was last updated on 9/30/2026 by MarketBeat.com Staff. From Our PartnersDr. Ron Paul Issues New Warning: “The Next Financial Crisis Is Here”Dr. Ron Paul warns a dangerous experiment is already underway in Washington, involving at least 27 billion dol...Altimetry | SponsoredThis AI Stock Reminds One Analyst of Early NvidiaJeff Brown picked Nvidia in 2016, before shares surged 37,800 percent. Now he's identified another AI company ...Brownstone Research | SponsoredYour book is insideThe "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...Profits Run | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredShould You Convert a Traditional IRA to a Roth After 60?Considering a Roth conversion after 60? The upside includes no income limits on conversions, potential tax-fre...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Globeimmune, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Globeimmune With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GBIM Stock Alerts